Intellia Therapeutics Inc buy BMO Capital Markets
Start price
10.11.23
/
50%
€22.58
Target price
10.11.24
€58.01
Performance (%)
-27.41%
Price
04.10.24
€16.39
Summary
This prediction is currently active. The price of Intellia Therapeutics Inc has decreased since the start of the prediction. Compared to the start price this results in a performance of -27.41%. This prediction currently runs until 10.11.24. The prediction end date can be changed by BMO_Capital_Markets at any time. BMO_Capital_Markets has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Intellia Therapeutics Inc | -12.912% | -12.912% |
iShares Core DAX® | -1.114% | 3.430% |
iShares Nasdaq 100 | 1.816% | 6.911% |
iShares Nikkei 225® | 2.113% | 5.501% |
iShares S&P 500 | 2.038% | 5.327% |
Comments by BMO_Capital_Markets for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at BMO Capital Markets from $64.00 to $62.00. They now have an "outperform" rating on the stock.
Ratings data for NTLA provided by MarketBeat
Stopped prediction by BMO_Capital_Markets for Intellia Therapeutics Inc
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€22.72
10.05.24
10.05.24
€64.98
10.05.25
10.05.25
-27.86%
04.10.24
04.10.24
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€36.37
13.03.23
13.03.23
-
13.03.24
13.03.24
-27.88%
14.03.24
14.03.24